Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Clin. transl. oncol. (Print) ; 24(5): 882-891, mayo 2022.
Article in English | IBECS | ID: ibc-203790

ABSTRACT

PurposeBreast cancer (BC) is one of the most common malignant tumors for women. The role and potential mechanisms of long non-coding RNA plasmacytoma variant translocation 1 (lncRNA PVT1) were explored in BC cell migration and invasion.MethodsPVT1, miR-148a-3p and Rho‑associated, coiled‑coil containing protein kinase 1 (ROCK1) mRNA expressions were detected using real-time fluorescent quantitative polymerase chain reaction (qRT-PCR). The ROCK1 protein expression was detected by Western blotting. The relationship of PVT1, miR-148a-3p and ROCK1 was analyzed by Dual Luciferase activity, RNA immunoprecipitation (RIP) and Spearman correlation analysis. Cell invasion and migration were detected by Transwell assay.ResultsUpregulation of PVT1 and ROCK1, and downregulation of miR-148a-3p were observed in BC tissues and cell lines. According to the analysis of Dual Luciferase activity, RIP and Spearman correlation analysis, miR-148a-3p directly binds to PVT1, and ROCK1 is a target of miR-148a-3p. In addition, PVT1 regulated the cells migration and invasion by regulating miR-148a-3p and ROCK1 expression.ConclusionThese data demonstrated that PVT1 was upregulated and facilitated to the cell migration and invasion of BC by the regulation of miR-148a-3p and ROCK1, indicating that PVT1 may be a potential biomarker of BC diagnosis and treatment.


Subject(s)
Humans , Unilateral Breast Neoplasms/genetics , Cell Movement/genetics , Cell Proliferation/genetics , Gene Expression Regulation, Neoplastic , Luciferases/metabolism , MicroRNAs/genetics , MicroRNAs/metabolism , RNA, Long Noncoding/genetics , RNA, Long Noncoding/metabolism
2.
Clin Transl Oncol ; 24(5): 882-891, 2022 May.
Article in English | MEDLINE | ID: mdl-34859371

ABSTRACT

PURPOSE: Breast cancer (BC) is one of the most common malignant tumors for women. The role and potential mechanisms of long non-coding RNA plasmacytoma variant translocation 1 (lncRNA PVT1) were explored in BC cell migration and invasion. METHODS: PVT1, miR-148a-3p and Rho­associated, coiled­coil containing protein kinase 1 (ROCK1) mRNA expressions were detected using real-time fluorescent quantitative polymerase chain reaction (qRT-PCR). The ROCK1 protein expression was detected by Western blotting. The relationship of PVT1, miR-148a-3p and ROCK1 was analyzed by Dual Luciferase activity, RNA immunoprecipitation (RIP) and Spearman correlation analysis. Cell invasion and migration were detected by Transwell assay. RESULTS: Upregulation of PVT1 and ROCK1, and downregulation of miR-148a-3p were observed in BC tissues and cell lines. According to the analysis of Dual Luciferase activity, RIP and Spearman correlation analysis, miR-148a-3p directly binds to PVT1, and ROCK1 is a target of miR-148a-3p. In addition, PVT1 regulated the cells migration and invasion by regulating miR-148a-3p and ROCK1 expression. CONCLUSION: These data demonstrated that PVT1 was upregulated and facilitated to the cell migration and invasion of BC by the regulation of miR-148a-3p and ROCK1, indicating that PVT1 may be a potential biomarker of BC diagnosis and treatment.


Subject(s)
Breast Neoplasms , MicroRNAs , RNA, Long Noncoding/genetics , Breast Neoplasms/genetics , Cell Line, Tumor , Cell Movement/genetics , Cell Proliferation/genetics , Female , Gene Expression Regulation, Neoplastic , Humans , Luciferases/metabolism , MicroRNAs/genetics , MicroRNAs/metabolism , RNA, Long Noncoding/metabolism , rho-Associated Kinases/genetics , rho-Associated Kinases/metabolism
3.
Clin. transl. oncol. (Print) ; 23(7): 1342-1349, jul. 2021. graf
Article in English | IBECS | ID: ibc-221974

ABSTRACT

Purpose This paper aims to observe the expressions of VEGF and MMP-2 in patients with nasopharyngeal carcinoma treated by nimotuzumab combined with cisplatin. Methods Altogether, 104 patients with nasopharyngeal carcinoma treated in our hospital from April 2014 to August 2016 were selected as research subjects. Among them, 50 patients treated with cisplatin were divided into a control group and 54 patients treated with nimotuzumab combined with cisplatin were divided into an observation group. The two groups of patients were compared in terms of efficacy after treatment and incidence of adverse reactions. Changes of serum VEGF and MMP-2 concentrations before and after treatment were detected using enzyme-linked immunosorbent assay (ELISA), and the 3-year overall survival (OS) of patients was observed. Results Compared with the control group, patients in the observation group had significantly higher total remission rate (RR) (P < 0.05) and significantly lower incidence of adverse reactions (P < 0.05). Before treatment, there was no significant difference between the observation and control groups in the concentrations of VEGF and MMP-2 (P > 0.05). After treatment, the concentrations in the two groups were significantly lower than those before treatment (P < 0.05), and the concentrations in the observation group were significantly lower than those in the control group (P < 0.05). There was no significant difference in the 3-year OS between the observation and control groups (P > 0.05). Conclusions Nimotuzumab combined with cisplatin could improve the conditions of patients with nasopharyngeal carcinoma. After treatment, the expression of VEGF and MMP-2 decreased significantly. We speculated that it improves the survival rate of patients by reducing the expression of VEGF and MMP-2 (AU)


Subject(s)
Humans , Male , Female , Adult , Antibodies, Monoclonal, Humanized/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Cisplatin/administration & dosage , Matrix Metalloproteinase 2 , Nasopharyngeal Neoplasms/drug therapy , Vascular Endothelial Growth Factor A
4.
Clin Transl Oncol ; 23(7): 1342-1349, 2021 Jul.
Article in English | MEDLINE | ID: mdl-33517541

ABSTRACT

PURPOSE: This paper aims to observe the expressions of VEGF and MMP-2 in patients with nasopharyngeal carcinoma treated by nimotuzumab combined with cisplatin. METHODS: Altogether, 104 patients with nasopharyngeal carcinoma treated in our hospital from April 2014 to August 2016 were selected as research subjects. Among them, 50 patients treated with cisplatin were divided into a control group and 54 patients treated with nimotuzumab combined with cisplatin were divided into an observation group. The two groups of patients were compared in terms of efficacy after treatment and incidence of adverse reactions. Changes of serum VEGF and MMP-2 concentrations before and after treatment were detected using enzyme-linked immunosorbent assay (ELISA), and the 3-year overall survival (OS) of patients was observed. RESULTS: Compared with the control group, patients in the observation group had significantly higher total remission rate (RR) (P < 0.05) and significantly lower incidence of adverse reactions (P < 0.05). Before treatment, there was no significant difference between the observation and control groups in the concentrations of VEGF and MMP-2 (P > 0.05). After treatment, the concentrations in the two groups were significantly lower than those before treatment (P < 0.05), and the concentrations in the observation group were significantly lower than those in the control group (P < 0.05). There was no significant difference in the 3-year OS between the observation and control groups (P > 0.05). CONCLUSIONS: Nimotuzumab combined with cisplatin could improve the conditions of patients with nasopharyngeal carcinoma. After treatment, the expression of VEGF and MMP-2 decreased significantly. We speculated that it improves the survival rate of patients by reducing the expression of VEGF and MMP-2.


Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cisplatin/administration & dosage , Matrix Metalloproteinase 2/drug effects , Nasopharyngeal Carcinoma/drug therapy , Nasopharyngeal Neoplasms/drug therapy , Vascular Endothelial Growth Factor A/drug effects , Adult , Antibodies, Monoclonal, Humanized/pharmacology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Cisplatin/pharmacology , Female , Humans , Male , Middle Aged
7.
Eur Rev Med Pharmacol Sci ; 23(15): 6612-6620, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31378903

ABSTRACT

OBJECTIVE: Glioma is one of the most frequent brain tumors in adults, and it has a low 5-year survival rate. MicroRNA-92a (miR-92a) has been reported to be upregulated and acted as an oncogene in many cancers. The purpose of this study was to explore the molecular mechanisms of miR-92a and kruppel-like factor 4 (KLF4) in glioma. PATIENTS AND METHODS: Western blotting assay and quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) were applied to calculate the relative expression of interest proteins and mRNAs. Luciferase ability assay was conducted to evaluate whether miR-92a was targeting to KLF4. RESULTS: A higher expression of miR-92a was observed in glioma tissues compared with the corresponding adjacent non-tumor tissues. The upregulation of miR-92a predicted poor prognostic characteristics of glioma. The overexpression miR-92a significantly promoted cell proliferation an invasion, while the knockdown of miR-92a presented the opposite results. MiR-92a bound to KLF4 and mediated the expression of KLF4 in glioma cells. The knockdown of miR-92a inhibited cell invasion-mediated EMT. Furthermore, the knockdown of miR-92a suppressed cell proliferation through the KLF4/AKT/mTOR signal pathway. CONCLUSIONS: MiR-92a promoted the proliferation through the KLF4/AKT/mTOR signal pathway in glioma. The newly identified miR-92a/KLF4/AKT/mTOR axis provides novel insight into the pathogenesis of glioma.


Subject(s)
Brain Neoplasms/genetics , Glioma/genetics , Kruppel-Like Transcription Factors/genetics , MicroRNAs/metabolism , Signal Transduction/genetics , Animals , Brain/pathology , Brain/surgery , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Brain Neoplasms/surgery , Cell Line, Tumor , Cell Movement/genetics , Cell Proliferation/genetics , Epithelial-Mesenchymal Transition/genetics , Female , Gene Expression Regulation, Neoplastic , Gene Knockdown Techniques , Glioma/mortality , Glioma/pathology , Glioma/surgery , Humans , Kaplan-Meier Estimate , Kruppel-Like Factor 4 , Kruppel-Like Transcription Factors/metabolism , Male , Mice , Middle Aged , Neoplasm Grading , Neoplasm Invasiveness/genetics , Prognosis , Proto-Oncogene Proteins c-akt/metabolism , TOR Serine-Threonine Kinases/metabolism , Up-Regulation , Xenograft Model Antitumor Assays
9.
Eur Rev Med Pharmacol Sci ; 23(10): 4419-4424, 2019 May.
Article in English | MEDLINE | ID: mdl-31173317

ABSTRACT

OBJECTIVE: To investigate the specific role of miR-23 in atrial fibrillation (AF) progression and explore the possible underlying mechanism. PATIENTS AND METHODS: Right atrial appendage (RAA) tissues were collected from 30 patients with AF and 30 patients with sinus rhythm (SR), respectively. The expression level of miR-23 was detected by quantitative Real time-polymerase chain reaction (qRT-PCR). Moreover, cell counting kit-8 and flow cytometry were performed to detect the proliferation and cell apoptosis of AC16 cells after transfection with miR-23 inhibitor and mimics. Furthermore, luciferase reporter gene assay and RNA immunoprecipitation assay were performed to uncover the possible underlying mechanism. RESULTS: In the present study, the expression level of miR-23 in RAA tissues of AF patients was significantly higher than that of SR patients. After knockdown of miR-23 in AC16 cells, the proliferation was inhibited and cell apoptosis was induced. However, overexpression of miR-23 significantly promoted cell growth and suppressed cell apoptosis. Further experiments revealed that transforming growth factor-b1 (TGF-ß1) was a direct target of miR-23. In addition, TGF-ß1 expression was positively correlated with miR-23 expression in AF tissues. CONCLUSIONS: Our findings indicated that miR-23 could promote the progression of AF via promoting TGF-ß1, which might serve as a new direction for interpreting the mechanism of AF development.


Subject(s)
Apoptosis/genetics , Atrial Fibrillation/genetics , Atrial Fibrillation/pathology , Fibroblasts/pathology , MicroRNAs/genetics , Transforming Growth Factor beta1/genetics , Atrial Appendage/metabolism , Cell Count , Cell Line , Cell Proliferation , Disease Progression , Gene Targeting , Humans
10.
Eur Rev Med Pharmacol Sci ; 19(17): 3266-9, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26400533

ABSTRACT

OBJECTIVE: Discuss the main points of diagnosis of cortriatrium; patient's color Doppler echocardiography (CDE), provide basis for clinical treatment. PATIENTS AND METHODS: Inspect 12 cortriatrium cases with CDE, 10 cases with cardiovascular angiography, 12 patients were confirmed by operation. Operations were all carried out under the moderate hypothermia cardiopulmonary bypass with intracardiac correction technique. Abnormal diaphragm in the left a trial was completely removed, and other combined heart malformations were also cured. RESULTS: Four cases for II A type, 1 case for II B type, 6 cases for II A type, 1 case for II B type. Among them, there were 7 cases for combined atrial septal defect, 5 cases for ventricular septal defect, 3 cases for patent ductus arteriosus, 6 cases for pulmonary arterial hypertension. Twelve children all survived, deformity correction was satisfactory, and after operation, recovery went on well in 6 months to 3 years. CONCLUSIONS: CDE has specific diagnostic value for cortriatrium; thus, it is the optimal method of diagnosing cortriatrium.


Subject(s)
Cardiopulmonary Bypass/methods , Echocardiography, Doppler/methods , Heart Defects, Congenital/diagnosis , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Male
11.
Neuroscience ; 286: 364-70, 2015 Feb 12.
Article in English | MEDLINE | ID: mdl-25498225

ABSTRACT

OBJECTIVE: Prenatal exposure to lipopolysaccharide (LPS) or high-fat diet (HFD) results in hippocampal impairment and cognitive deficits in offspring rats. What is not clear is how prenatal exposure to LPS combined with pre- and post-natal HFD would affect the hippocampus in offspring rats. METHODS: 32 pregnant rats were randomly divided into four groups, including control group; LPS group (pregnant rats were injected with LPS 0.4 mg/kg intraperitoneally on the 8th, 10th and 12th day of pregnancy); HFD group (maternal rats had HFD during pregnancy and the lactation period, and their pups also had HFD up to the third month of life); LPS+HFD group (rats were exposed to the identical experimental scheme with LPS group and HFD group). The serum IL-6 and TNF-alpha concentration was measured in three-month-old offspring rats in all groups. Hippocampal morphology and expressions of glial fibrillary acidic protein (GFAP), Tau and synaptophysin (SYP) in offspring rats were measured. RESULTS: Serum IL-6 and TNF-alpha concentration in the HFD group increased significantly compared with the control group, LPS group and LPS+HFD group. Compared with the control group and the LPS+HFD group, cells in the LPS and HFD groups were smaller and arranged in disorder, and cell membrane was not complete, nucleoli and nuclear heterochromatin stained darkly with hematoxylin. GFAP and Tau expression in the hippocampus of the LPS and HFD groups increased significantly compared with the control group and LPS+HFD group. SYP expression in the LPS and HFD groups decreased significantly compared with the control group and HFD group, increased in the LPS+HFD group. CONCLUSION: Prenatal exposure to LPS combined with pre- and post-natal HFD result in a protective effect on the hippocampus in offspring rats, and it might be a benefit from the predictive adaptive response to prenatal inflammation.


Subject(s)
Diet, High-Fat/adverse effects , Hippocampus/metabolism , Lipopolysaccharides/toxicity , Prenatal Exposure Delayed Effects/metabolism , Animals , Female , Glial Fibrillary Acidic Protein/metabolism , Inflammation/metabolism , Interleukin-6/blood , Male , Pregnancy , Rats , Rats, Sprague-Dawley , Synaptophysin/metabolism , Tumor Necrosis Factor-alpha/blood , tau Proteins/metabolism
12.
Genet Mol Res ; 10(4): 3013-9, 2011 Dec 06.
Article in English | MEDLINE | ID: mdl-22180034

ABSTRACT

Carnitine is involved in fatty acid metabolism in mammals and is widely used as a nutritional supplement; carnitine orotate is a more absorbable form of carnitine. We investigated the effects of carnitine and carnitine orotate on mouse prolactin-releasing peptide (PrRP) mRNA expression. Twenty-four female mice were randomly divided into four groups of six; control mice were orally drenched with physiological saline solution (250 mg/kg body weight) and treatment mice were orally drenched with carnitine (250 mg/kg) or carnitine orotate (250 or 750 mg/kg), once a day, for 20 days from parturition. The carnitine or carnitine orotate was dissolved in saline solution before administration. The hypothalamus, pituitary and ovary were sampled on day 21 after parturition, and PrRP mRNA levels in these tissues were measured by semi-quantitative PCR, with glyceraldehyde 3-phosphate dehydrogenase as a control. Expression of PrRP in mice treated with carnitine and carnitine orotate was significantly increased in the ovary and significantly reduced in the pituitary gland. Compared with the control, hypothalamus PrRP mRNA increased significantly in the carnitine and low-dose carnitine orotate groups and decreased significantly in the high-dose carnitine orotate group. We conclude that carnitine and carnitine orotate regulate expression of PrRP in the pituitary gland and ovaries.


Subject(s)
Carnitine/administration & dosage , Gene Expression/drug effects , Hypothalamus/drug effects , Ovary/drug effects , Pituitary Gland/drug effects , Prolactin-Releasing Hormone/metabolism , Administration, Oral , Animals , Carnitine/analogs & derivatives , Drug Administration Schedule , Female , Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+)/genetics , Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+)/metabolism , Hypothalamus/metabolism , Mice , Organ Specificity , Ovary/metabolism , Pituitary Gland/metabolism , Pregnancy , Prolactin-Releasing Hormone/genetics , RNA, Messenger/analysis , RNA, Messenger/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction
13.
Genet Mol Res ; 10(2): 615-20, 2011 Apr 12.
Article in English | MEDLINE | ID: mdl-21491371

ABSTRACT

We compared levels of prolactin-releasing peptide (PrRP) mRNA expression in mouse medulla at different stages of pregnancy and lactation. Mouse medulla samples were collected on days 6, 12 and 18 of pregnancy and lactation, respectively (six per group), for mRNA. Expression levels of PrRP mRNA in the medulla were measured by semi-quantitative RT-PCR, with glyceraldehyde 3-phosphate dehydrogenase as a control. PrRP mRNA was highly expressed in mouse medulla oblongata on day 6 of pregnancy (0.53), followed by 0.43 at lactation day 6, and 0.42 at lactation day 12. The expression level of PrRP mRNA on days 12 and 18 of pregnancy and day 18 of lactation shared the same value of 0.36. PrRP mRNA levels during lactation decreased slightly compared with that during pregnancy, but the differences between them were not significant. In summary, PrRP mRNA levels in the medulla oblongata remain relatively stable during pregnancy and lactation. This is evidence that medulla PrRP is not involved in the regulation of prolactin secretion.


Subject(s)
Medulla Oblongata , Prolactin-Releasing Hormone/biosynthesis , Prolactin-Releasing Hormone/genetics , Animals , Female , Gene Expression , Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+)/genetics , Lactation , Medulla Oblongata/cytology , Medulla Oblongata/enzymology , Medulla Oblongata/metabolism , Mice , Pituitary Hormones, Anterior/metabolism , Pregnancy , Prolactin/metabolism , RNA, Messenger , Reverse Transcriptase Polymerase Chain Reaction
14.
Oncogene ; 26(16): 2365-73, 2007 Apr 05.
Article in English | MEDLINE | ID: mdl-17016435

ABSTRACT

In response to gamma-radiation-induced DNA damage, organisms either activate cell cycle checkpoint and repair machinery or undergo apoptosis to eliminate damaged cells. Although previous studies indicated that the tumor suppressor p53 is critically involved in mediating both responses, how a cell decides which pathway to take is not well established. The zinc-finger-containing transcription factor, Krüppel-like factor 4 (KLF4), is a crucial mediator for the checkpoint functions of p53 after gamma-irradiation and does so by inhibiting the transition from the G(1) to S and G(2) to M phases of the cell cycle. Here, we determined the role of KLF4 in modulating the apoptotic response following gamma-irradiation. In three independent cell systems including colorectal cancer cells and mouse embryo fibroblasts in which expression of KLF4 could be manipulated, we observed that gamma-irradiated cells underwent apoptosis if KLF4 was absent. In the presence of KLF4, the degree of apoptosis was significantly reduced and cells resorted to checkpoint arrest. The mechanism by which KLF4 accomplished this antiapoptotic effect is by activating expression of the cell cycle arrest gene, p21(WAF1/CIP1), and by inhibiting the ability of p53 to transactivate expression of the proapoptotic gene, BAX. Results of our study illustrate an unexpected antiapoptotic function of KLF4, heretofore considered a tumor suppressor in colorectal cancer, and suggest that KLF4 may be an important determinant of cell fate following gamma-radiation-induced DNA damage.


Subject(s)
Apoptosis/radiation effects , DNA, Neoplasm/radiation effects , Kruppel-Like Transcription Factors/physiology , Animals , COS Cells , Cell Cycle/radiation effects , Cell Line, Tumor , Chlorocebus aethiops , DNA Damage , DNA Primers , DNA, Neoplasm/genetics , Flow Cytometry , Gamma Rays , Humans , Kruppel-Like Factor 4 , Kruppel-Like Transcription Factors/radiation effects , Promoter Regions, Genetic , Transfection , Tumor Suppressor Protein p53/radiation effects , bcl-2-Associated X Protein/genetics
15.
Talanta ; 57(1): 53-7, 2002 Apr 22.
Article in English | MEDLINE | ID: mdl-18968604

ABSTRACT

A selective flow injection electrogenerated chemiluminescence(CL) method for the determination of vanadium is described in this paper. It was based on the chemiluminescence reaction of luminol with vanadium(II), which was on-line electrogenerated from vanadate using a flow-through carbon electrolytic cell. Under the optimal conditions, the CL intensity was linear to the concentration of vanadium in the range of 5.0x10(-10)-1.0x10(-7) gml(-1) with a detection limit of 2x10(-10) gml(-1) vanadium. The relative standard deviation was 4% for 5.0x10(-8) gml(-1) vanadium in 11 repeated measurements. The method has been successfully applied to the determination of vanadium in environmental water samples.

16.
Appl Biochem Biotechnol ; 84-86: 543-59, 2000.
Article in English | MEDLINE | ID: mdl-10849818

ABSTRACT

Ethanol and glycerol are both metabolic products of yeasts. There are occasions when coproduction of both is considered desirable in industrial operations. In this article, we describe the potential of integrating the two processes. A LORRE Y8 yeast culture isolated from molasses is capable of efficient glycerol production from glucose, and a yeast Culture 1400 is an excellent producer of ethanol. By controlling the process conditions, the ratio of ethanol and glycerol production can be varied.


Subject(s)
Ethanol , Glycerol , Saccharomyces/growth & development , Bioreactors , Biotechnology/instrumentation , Biotechnology/methods , Fermentation , Glucose/metabolism , Soaps
17.
Chin Med J (Engl) ; 107(8): 583-8, 1994 Aug.
Article in English | MEDLINE | ID: mdl-7805441

ABSTRACT

Intracerebral co-grafting of Schwann's cells and human fetal adrenal medullary tissue was performed in 10 patients with Parkinson's disease. One to six months after grafting, symptoms were improved significantly for 1 to 3 grade. Among them, 2 patients resumed nearly normal daily activities. Long-term follow-up showed that the symptoms were not improved satisfactorily in some patients. It is considered that careful selection of patients, administration of amantadine, and co-grafting of Schwann's cells which prompts the survival of chromaffin cells are essential to better results.


Subject(s)
Adrenal Medulla/transplantation , Brain Tissue Transplantation , Brain/surgery , Fetal Tissue Transplantation , Parkinson Disease/surgery , Schwann Cells/transplantation , Adrenal Medulla/embryology , Adult , Amantadine/therapeutic use , Female , Follow-Up Studies , Humans , Male , Middle Aged , Sural Nerve/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...